A Phase 1, Randomized, Double-Blind, Placebo-Controlled StudyTo Evaluate The Safety, Tolerability, And Pharmacokinetics Of Multiple Ascending Doses Of AUM001 In Normal Healthy Volunteers
Latest Information Update: 18 May 2020
At a glance
- Drugs AUM 001 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AUM Biosciences
- 18 May 2020 New trial record